New trends in classification, diagnosis and treatment of chronic obstructive pulmonary disease


Cite item

Full Text

About the authors

I V Leschenko

References

  1. Хронические обструктивные болезни легких. Федеральная программа. М.; 1999.
  2. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Bethesda: National Heart, Lung and Blood Institute, April 2001; NIH Publication N 2701.
  3. Овчаренко С. И., Лещенко И. В. Современные проблемы диагностики хронической обструктивной болезни легких. Рус. мед. журн. 2003; 11 (4): 160-163.
  4. Авдеев С. Н. Роль антихолинергических препаратов при обструктивных заболеваниях легких. Consilium Medicum 2002; 4 (9): 478-485.
  5. Илькович М. М., Игнатьев В. А. ХОБЛ: нозологическая форма или группа заболеваний? Атмосфера. Аллерг. и респир. забол. 2002; 1 (4): 27-28.
  6. Синопальников А. И., Клячкшш И. Л. Бронхолитическая терапия больных со стабильным течением хронической обструктивной болезни легких. Рус. мед. журн. 2002; 10 (16): 701-706.
  7. Цой А. П., Архипов В. В. Доказательная фармакотерапия хронической обструктивной болезни легких. Consilium Medicum 2002; 4 (9): 486-492.
  8. Шмелев Е. И. Различия в диагностике и лечении бронхиальной астмы и хронической обструктивной болезни легких. Consilium Medicum 2002; 4 (9): 492-497.
  9. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Bethesda: National Heart, Lung and Blood Institute, April 2001; Update of the Management Sections, GOLD website (www.goldcopd.com). Date update: 1 July 2002.
  10. Fabbri L. M., Hurd S. S. Global strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur. Respir. J. 2003; 22: 1-2.
  11. Barnes P. J. Bronchodilators: basic pharmacology. In: Calverley P. M. A., Pride N. В., eds. Chronic obstructive pulmonary disease. London: Chapman and Hall; 1995; 391-417.
  12. Guyatt G. H., Townsend M., Puqsley S. O. et al. Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity and quality of life. Am. Rev. Respir. Dis. 1987; 135: 1069-1074.
  13. Ikeda A., Nishimura K., Koyama N. et al. Dose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary disease. Thorax 1996; 51: 48-53.
  14. van Schayck C. P., Folgering H., Barbers H. et al. Effects of allergy and age on responses to salbutamol and ipratropium bromide in moderate asthma and chronic bronchitis. Thorax 1991; 46: 355-359.
  15. Sestini P. et al. Short-acting P2-agonist for stable COPD (Cochran Review). In: The Cochran library. Oxford: Update Software; 2001; Issue 4.
  16. Barnes P. Muscarinic receptor subtypes in airways. Life Sci. 1993; 52: 521-527.
  17. Gross N. J., Skorodin M. S. Anthicholinergic antimuscarinic bronchodilators. Am. Rev. Respir. Dis. 1984; 129: 856-870.
  18. Rennard S. I., Serby С. W., Ghafouri M. et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest 1996; 110 (1): 62-70.
  19. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD). Am. J. Respir. Crit. Care Med. 1995; 152:77.
  20. Barnes P. The pharmacological properties of tiotropium. Chest 2000; 117: S63-S69.
  21. Littner M. R., Auerbach D., Campbell S. et al. The bronchodilator effects of tiotropium in stable COPD. Am. J. Respir. Crit. Care Med. 1997; 155: A282.
  22. Littner M. R., Illowite J. S., Tashkin D. P. et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary/disease. Am. J. Respir. Crit. Caare Med. 2000; 161: 1136-1142.
  23. Jones P. Personal communication. 10-/11 European Respiratory Society. Annual conference (ERSV Florence, Italy, 30 August-3 September 2Q00. www.medscape.com/ConferenceSearchAH.ctm/.
  24. Vincken W., van Noord J. A., Greefhorst A. P. M. et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 2002; 19: 209-216.
  25. Casaburi R., Mahler D. A., Jones P. W. et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Resp. J. 2002; 19: 217-224.
  26. Ulrik С. S. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single center randomized, double blind, placebo controlled, crossover study. Thorax 1995; 50: 750-754.
  27. Boyd G., Morice A. H., Pounsford J. C. et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur. Respir. J. 1997; 10: 815-821.
  28. Rossi A., Kristufec K., Levine В. E. et al. Comparison of the efficacy, tolerability and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002; 121: 1058-1069.
  29. Mahler D. A., Donohue J. E., Barbae R. A. et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115:957-965.
  30. Dahl R., Greefhorst L. A., Nowak D. et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 778-784.
  31. Donohue J. F., van Noord J. A., Bateman E. D. et al. A 6 month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.
  32. van Noord J. A., de Munck D. A., Bantje T. A. et al. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur. Respir. J. 2000; 15: 878-885.
  33. Hllleman D. E., Dewan N., Malesker M. et al. Pharmacoeconomic evaluation of COPD. Chest 2000: 118: 1278-1285.
  34. Tashkin D. P., Bleecker E., Braun S. et al. Results of multi combination in chronic obstructive pulmonary disease center study of nebulized inhalant bronchodilator solutions. Am. J. Med. 1996; 100: 62-69.
  35. The COMB1VENT inhalation solution study group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997; 112: 1514-1521.
  36. Gross N., Tashkin D. P., Miller R. et al. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey combination solution study group. Respiration 1998; 65: 354-362.
  37. Zu Wallack R. L., Mahler D. A., Reilly D. et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119: 1661-1670.
  38. Vestbo J., Sorensen Т., Lange P. et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 1999; 353: 1819-1823.
  39. Pauwels R. A., Lofdahl С. G., Laitinen L. A. et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstmctive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. 1999; 340: 1948-1953.
  40. Burge P. S., Calverley P. M., Jones P. W. et al. Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000; 320: 1297-1303.
  41. Jones P. W., Willits L. R., Burge P. S. et al. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur. Respir. J. 2003; 21: 68- 73.
  42. Calverley P. M., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003; 361: 449- 456.
  43. Mahler D. A., Wire P., Horstman D. et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166 (8): 1084-1091.
  44. Lyseng-Williamson K. A., Keating G. Inhaled salmeterol/fiuticasone propionate combination in chronic obstructive pulmonary disease. Am. J. Respir. Med. 2002; 1 (4): 273-283.
  45. Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 74-81.
  46. Rice K. L., Rubins J. В., Lebahn F. et al. Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial. Am. J. Respir. Crit. Care Med. 2000; 162: 174- 178.
  47. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1995; 152: S77-S121.
  48. Siafakas N. M., Vermeire P., Pride N. B. et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). A consensus statement of the European Respiratory Society (ERS). Eur. Respir. J. 1995; 8: 1398-1420.
  49. Nichol K. L., Margolis K. L., Wuorenma J., Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N. Engl. J. Med. 1994; 331: 778-784.
  50. Berry M. J., Rejeski W. J., Adair N. E., Zaccaro D. Exercise rehabilitation and chronic obstructive pulmonary disease stage. Am. J. Respir. Crit. Care Med. 1999; 160: 1248-1253.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies